{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T07:06:21Z","timestamp":1789628781398,"version":"build-2803163510"},"reference-count":82,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T00:00:00Z","timestamp":1786492800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","award":["LX22NPO5104"],"award-info":[{"award-number":["LX22NPO5104"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003243","name":"Ministerstvo Zdravotnictv\u00ed Cesk\u00e9 Republiky","doi-asserted-by":"publisher","award":["NU20-02-00190"],"award-info":[{"award-number":["NU20-02-00190"]}],"id":[{"id":"10.13039\/501100003243","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003243","name":"Ministerstvo Zdravotnictv\u00ed Cesk\u00e9 Republiky","doi-asserted-by":"publisher","award":["NV19-02-00118"],"award-info":[{"award-number":["NV19-02-00118"]}],"id":[{"id":"10.13039\/501100003243","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001824","name":"Grantov\u00e1 Agentura \u010cesk\u00e9 Republiky","doi-asserted-by":"publisher","award":["25-15252S"],"award-info":[{"award-number":["25-15252S"]}],"id":[{"id":"10.13039\/501100001824","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Molecular and Cellular Cardiology Plus"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.jmccpl.2026.100860","type":"journal-article","created":{"date-parts":[[2026,8,16]],"date-time":"2026-08-16T22:00:36Z","timestamp":1786917636000},"page":"100860","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["SGLT2 inhibitor therapy is associated with IL-10\/TGF-\u03b1\/sVEGFR3 signalling and adipose tissue remodelling in advanced heart failure"],"prefix":"10.1016","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0174-2933","authenticated-orcid":false,"given":"Anna","family":"Cinkajzlova","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4578-1093","authenticated-orcid":false,"given":"Barbora Judita","family":"Kasperova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1803-604X","authenticated-orcid":false,"given":"Peter","family":"Ivak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1567-7036","authenticated-orcid":false,"given":"Ivan","family":"Netuka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8921-7078","authenticated-orcid":false,"given":"Vojtech","family":"Melenovsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4347-7768","authenticated-orcid":false,"given":"Lenka Steiner","family":"Mrazova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2599-6479","authenticated-orcid":false,"given":"Viktor","family":"Stranecky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5322-4612","authenticated-orcid":false,"given":"Milos","family":"Mraz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3454-6840","authenticated-orcid":false,"given":"Sona","family":"Stemberkova Hubackova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0201-6888","authenticated-orcid":false,"given":"Martin","family":"Haluzik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jmccpl.2026.100860_bb0005","series-title":"StatPearls","article-title":"Congestive heart failure","author":"Malik","year":"2025"},{"issue":"1","key":"10.1016\/j.jmccpl.2026.100860_bb0010","doi-asserted-by":"crossref","first-page":"63","DOI":"10.5152\/akd.2014.5731","article-title":"Mortality in heart failure patients","volume":"15","author":"Byty\u00e7i","year":"2015","journal-title":"Anatol J Cardiol"},{"issue":"8","key":"10.1016\/j.jmccpl.2026.100860_bb0015","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1038\/s41569-024-00997-0","article-title":"Contemporary pharmacological treatment and management of heart failure","volume":"21","author":"Bozkurt","year":"2024","journal-title":"Nat Rev Cardiol"},{"issue":"16","key":"10.1016\/j.jmccpl.2026.100860_bb0020","doi-asserted-by":"crossref","DOI":"10.3390\/jcm12165217","article-title":"The ABC of heart transplantation-part 1: indication, eligibility, donor selection, and surgical technique","volume":"12","author":"Masarone","year":"2023","journal-title":"J Clin Med"},{"issue":"17","key":"10.1016\/j.jmccpl.2026.100860_bb0025","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1056\/NEJMoa1900486","article-title":"A fully magnetically levitated left ventricular assist device - final report","volume":"380","author":"Mehra","year":"2019","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.jmccpl.2026.100860_bb0030","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1001\/jama.2022.16197","article-title":"Five-year outcomes in patients with fully magnetically levitated vs axial-flow left ventricular assist devices in the MOMENTUM 3 randomized trial","volume":"328","author":"Mehra","year":"2022","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.jmccpl.2026.100860_bb0035","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1002\/ejhf.1284","article-title":"Long-term evaluation of a fully magnetically levitated circulatory support device for advanced heart failure-two-year results from the HeartMate 3CE Mark study","volume":"21","author":"Schmitto","year":"2019","journal-title":"Eur J Heart Fail"},{"issue":"2","key":"10.1016\/j.jmccpl.2026.100860_bb0040","doi-asserted-by":"crossref","first-page":"82","DOI":"10.36628\/ijhf.2022.0030","article-title":"SGLT-2 inhibitors in heart failure: a review of current evidence","volume":"5","author":"Talha","year":"2023","journal-title":"Int J Heart Fail"},{"key":"10.1016\/j.jmccpl.2026.100860_bb0045","doi-asserted-by":"crossref","first-page":"161","DOI":"10.2147\/DMSO.S233538","article-title":"Extraglycemic effects of SGLT2 inhibitors: a review of the evidence","volume":"13","author":"Bonora","year":"2020","journal-title":"Diabetes Metab Syndr Obes"},{"issue":"8","key":"10.1016\/j.jmccpl.2026.100860_bb0050","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/nrendo.2011.243","article-title":"SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects","volume":"8","author":"Ferrannini","year":"2012","journal-title":"Nat Rev Endocrinol"},{"issue":"22","key":"10.1016\/j.jmccpl.2026.100860_bb0055","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"issue":"17","key":"10.1016\/j.jmccpl.2026.100860_bb0060","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1161\/CIRCULATIONAHA.117.030012","article-title":"Sodium glucose cotransporter-2 inhibition in heart failure: potential mechanisms, clinical applications, and summary of clinical trials","volume":"136","author":"Lytvyn","year":"2017","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.jmccpl.2026.100860_bb0065","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1186\/s12933-017-0621-8","article-title":"Dapagliflozin acutely improves endothelial dysfunction, reduces aortic stiffness and renal resistive index in type 2 diabetic patients: a pilot study","volume":"16","author":"Solini","year":"2017","journal-title":"Cardiovasc Diabetol"},{"issue":"7","key":"10.1016\/j.jmccpl.2026.100860_bb0070","doi-asserted-by":"crossref","DOI":"10.14814\/phy2.15990","article-title":"Dapagliflozin prevents ERK activation and SGLT2-dependent endoglin upregulation in a mechanically provoked cardiac injury model","volume":"12","author":"Yeh","year":"2024","journal-title":"Physiol Rep"},{"issue":"22","key":"10.1016\/j.jmccpl.2026.100860_bb0075","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.124.035044","article-title":"Empagliflozin attenuates neointima formation after arterial injury and inhibits smooth muscle cell proliferation and migration by suppressing platelet-derived growth factor-related signaling","volume":"13","author":"Chang","year":"2024","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jmccpl.2026.100860_bb0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.117589","article-title":"Empagliflozin attenuating renal interstitial fibrosis in diabetic kidney disease by inhibiting lymphangiogenesis and lymphatic endothelial-to-mesenchymal transition via the VEGF-C\/VEGFR3 pathway","volume":"180","author":"Huang","year":"2024","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.jmccpl.2026.100860_bb0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2023.176066","article-title":"Reversal of fibrosis and portal hypertension by Empagliflozin treatment of CCl4-induced liver fibrosis: emphasis on gal-1\/NRP-1\/TGF-\u03b2 and gal-1\/NRP-1\/VEGFR2 pathways","volume":"959","author":"Noah","year":"2023","journal-title":"Eur J Pharmacol"},{"issue":"3","key":"10.1016\/j.jmccpl.2026.100860_bb0090","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1002\/ejhf.2115","volume":"23","author":"Bozkurt","year":"2021","journal-title":"Eur J Heart Fail"},{"issue":"8","key":"10.1016\/j.jmccpl.2026.100860_bb0095","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.30754","article-title":"Time to benefit of sodium-glucose cotransporter-2 inhibitors among patients with heart failure","volume":"6","author":"Chen","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"20","key":"10.1016\/j.jmccpl.2026.100860_bb0100","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects","volume":"310","author":"World Medical Association","year":"2013","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.jmccpl.2026.100860_bb0105","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1186\/s12933-024-02298-9","article-title":"Sodium-glucose cotransporter 2 inhibitors induce anti-inflammatory and anti-ferroptotic shift in epicardial adipose tissue of subjects with severe heart failure","volume":"23","author":"Kasperova","year":"2024","journal-title":"Cardiovasc Diabetol"},{"issue":"D1","key":"10.1016\/j.jmccpl.2026.100860_bb0110","doi-asserted-by":"crossref","first-page":"D933","DOI":"10.1093\/nar\/gkac958","article-title":"Ensembl 2023","volume":"51","author":"Martin","year":"2023","journal-title":"Nucleic Acids Res"},{"issue":"5","key":"10.1016\/j.jmccpl.2026.100860_bb0115","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.ando.2020.07.1113","article-title":"The plasma levels of atrial natriuretic peptide and brain natriuretic peptide in type 2 diabetes treated with sodium-glucose cotransporter-2 inhibitor","volume":"81","author":"Feng","year":"2020","journal-title":"Ann Endocrinol"},{"issue":"4","key":"10.1016\/j.jmccpl.2026.100860_bb0120","doi-asserted-by":"crossref","DOI":"10.3390\/ijms26041670","article-title":"Anti-inflammatory effects of SGLT2 inhibitors: focus on macrophages","volume":"26","author":"Rykova","year":"2025","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.jmccpl.2026.100860_bb0125","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1097\/SHK.0b013e3181b7d137","article-title":"Preconditioning mesenchymal stem cells with transforming growth factor-alpha improves mesenchymal stem cell-mediated cardioprotection","volume":"33","author":"Herrmann","year":"2010","journal-title":"Shock"},{"key":"10.1016\/j.jmccpl.2026.100860_bb0130","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1446300","article-title":"CDKN1A as a target of senescence in heart failure: insights from a multiomics study","volume":"15","author":"Bian","year":"2024","journal-title":"Front Pharmacol"},{"issue":"4","key":"10.1016\/j.jmccpl.2026.100860_bb0135","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1038\/labinvest.3700241","article-title":"P53-dependent ICAM-1 overexpression in senescent human cells identified in atherosclerotic lesions","volume":"85","author":"Gorgoulis","year":"2005","journal-title":"Lab Invest"},{"issue":"17","key":"10.1016\/j.jmccpl.2026.100860_bb0140","doi-asserted-by":"crossref","first-page":"3272","DOI":"10.1093\/cvr\/cvac013","article-title":"Global burden of heart failure: a comprehensive and updated review of epidemiology","volume":"118","author":"Savarese","year":"2022","journal-title":"Cardiovasc Res"},{"issue":"10","key":"10.1016\/j.jmccpl.2026.100860_bb0145","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1007\/s00125-018-4669-0","article-title":"The actions of SGLT2 inhibitors on metabolism, renal function and blood pressure","volume":"61","author":"Thomas","year":"2018","journal-title":"Diabetologia"},{"key":"10.1016\/j.jmccpl.2026.100860_bb0150","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.freeradbiomed.2017.01.035","article-title":"Dapagliflozin, a selective SGLT2 inhibitor, attenuated cardiac fibrosis by regulating the macrophage polarization via STAT3 signaling in infarcted rat hearts","volume":"104","author":"Lee","year":"2017","journal-title":"Free Radic Biol Med"},{"key":"10.1016\/j.jmccpl.2026.100860_bb0155","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.ebiom.2017.05.028","article-title":"SGLT2 inhibition by empagliflozin promotes fat utilization and browning and attenuates inflammation and insulin resistance by polarizing M2 macrophages in diet-induced obese mice","volume":"20","author":"Xu","year":"2017","journal-title":"EBioMedicine"},{"issue":"17","key":"10.1016\/j.jmccpl.2026.100860_bb0160","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.133050","article-title":"IL-10 provides cardioprotection in diabetic myocardial infarction via upregulation of heme clearance pathways","volume":"5","author":"Gupta","year":"2020","journal-title":"JCI Insight"},{"issue":"4","key":"10.1016\/j.jmccpl.2026.100860_bb0165","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1161\/CIRCULATIONAHA.112.112185","article-title":"Interleukin-10 treatment attenuates pressure overload\u2013induced hypertrophic remodeling and improves heart function via signal transducers and activators of transcription 3\u2013dependent inhibition of nuclear factor-\u03baB","volume":"126","author":"Verma","year":"2012","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.jmccpl.2026.100860_bb0170","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1016\/j.athoracsur.2011.06.057","article-title":"Transforming growth factor-&#x3b1; enhances stem cell-mediated postischemic myocardial protection","volume":"92","author":"Herrmann","year":"2011","journal-title":"Ann Thorac Surg"},{"issue":"4866","key":"10.1016\/j.jmccpl.2026.100860_bb0175","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1126\/science.3041594","article-title":"Wound macrophages express TGF-\u03b1 and other growth factors in vivo: analysis by mRNA phenotyping","volume":"241","author":"Rappolee","year":"1988","journal-title":"Science"},{"issue":"12","key":"10.1016\/j.jmccpl.2026.100860_bb0180","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1161\/01.RES.0000130526.20854.fa","article-title":"Inflammatory cytokines and postmyocardial infarction remodeling","volume":"94","author":"Nian","year":"2004","journal-title":"Circ Res"},{"issue":"4","key":"10.1016\/j.jmccpl.2026.100860_bb0185","doi-asserted-by":"crossref","first-page":"R1115","DOI":"10.1152\/ajpregu.90383.2008","article-title":"TGF-\u03b1 increases human mesenchymal stem cell-secreted VEGF by MEK- and PI3-K- but not JNK- or ERK-dependent mechanisms","volume":"295","author":"Wang","year":"2008","journal-title":"Am J Physiol-Regul Integr Comp Physiol"},{"issue":"5","key":"10.1016\/j.jmccpl.2026.100860_bb0190","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines12051055","article-title":"Vascular endothelial growth factor (VEGF) and its role in the cardiovascular system","volume":"12","author":"Florek","year":"2024","journal-title":"Biomedicines"},{"key":"10.1016\/j.jmccpl.2026.100860_bb0195","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1349500","article-title":"VEGFR-3 signaling in macrophages: friend or foe in disease?","volume":"15","author":"Kannan","year":"2024","journal-title":"Front Immunol"},{"issue":"3","key":"10.1016\/j.jmccpl.2026.100860_bb0200","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.374","article-title":"VEGF-C\/VEGFR-3 axis protects against pressure-overload induced cardiac dysfunction through regulation of lymphangiogenesis","volume":"11","author":"Lin","year":"2021","journal-title":"Clin Transl Med"},{"issue":"3\u20134","key":"10.1016\/j.jmccpl.2026.100860_bb0205","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1007\/s10495-024-02068-8","article-title":"sVEGFR3 alleviates myocardial ischemia\/reperfusion injury through regulating mitochondrial homeostasis and immune cell infiltration","volume":"30","author":"Shang","year":"2025","journal-title":"Apoptosis"},{"issue":"7","key":"10.1016\/j.jmccpl.2026.100860_bb0210","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1161\/ATVBAHA.120.314370","article-title":"Lymphatic and immune cell cross-talk regulates cardiac recovery after experimental myocardial infarction","volume":"40","author":"Houssari","year":"2020","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"4","key":"10.1016\/j.jmccpl.2026.100860_bb0215","doi-asserted-by":"crossref","first-page":"R1115","DOI":"10.1152\/ajpregu.90383.2008","article-title":"TGF-alpha increases human mesenchymal stem cell-secreted VEGF by MEK- and PI3-K- but not JNK- or ERK-dependent mechanisms","volume":"295","author":"Wang","year":"2008","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"issue":"2","key":"10.1016\/j.jmccpl.2026.100860_bb0220","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/micc.12259","article-title":"Macrophages: an inflammatory link between angiogenesis and lymphangiogenesis","volume":"23","author":"Corliss","year":"2016","journal-title":"Microcirculation"},{"issue":"6","key":"10.1016\/j.jmccpl.2026.100860_bb0225","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1007\/s10741-017-9644-1","article-title":"Epicardial adipose tissue as a metabolic transducer: role in heart failure and coronary artery disease","volume":"22","author":"Patel","year":"2017","journal-title":"Heart Fail Rev"},{"key":"10.1016\/j.jmccpl.2026.100860_bb0230","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1146\/annurev-physiol-042222-021346","article-title":"Adipose tissue in cardiovascular disease: from basic science to clinical translation","volume":"86","author":"Polkinghorne","year":"2024","journal-title":"Annu Rev Physiol"},{"issue":"1","key":"10.1016\/j.jmccpl.2026.100860_bb0235","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s10741-020-09997-x","article-title":"The roles of epicardial adipose tissue in heart failure","volume":"27","author":"Song","year":"2022","journal-title":"Heart Fail Rev"},{"issue":"1","key":"10.1016\/j.jmccpl.2026.100860_bb0240","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1186\/s12933-024-02539-x","article-title":"SGLT2 inhibition and adipose tissue metabolism: current outlook and perspectives","volume":"23","author":"Morciano","year":"2024","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"10.1016\/j.jmccpl.2026.100860_bb0245","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s11897-014-0231-7","article-title":"Targeting interleukin-1 in heart failure and inflammatory heart disease","volume":"12","author":"Van Tassell","year":"2015","journal-title":"Curr Heart Fail Rep"},{"key":"10.1016\/j.jmccpl.2026.100860_bb0250","article-title":"Role of the CCL2-CCR2 axis in cardiovascular disease: pathogenesis and clinical implications","volume":"13","author":"Zhang","year":"2022","journal-title":"Front Immunol"},{"issue":"9","key":"10.1016\/j.jmccpl.2026.100860_bb0255","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1007\/s00204-015-1477-x","article-title":"Pathophysiology of cardiac hypertrophy and heart failure: signaling pathways and novel therapeutic targets","volume":"89","author":"Tham","year":"2015","journal-title":"Arch Toxicol"},{"key":"10.1016\/j.jmccpl.2026.100860_bb0260","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2025.1622107","article-title":"Coming of age: could obesity-related metabolic complications be treated by targeting senescent cells?","volume":"13","author":"Kasperova","year":"2025","journal-title":"Front Cell Dev Biol"},{"issue":"2","key":"10.1016\/j.jmccpl.2026.100860_bb0265","doi-asserted-by":"crossref","first-page":"102","DOI":"10.3934\/Allergy.2021009","article-title":"Role of RP105 and A20 in negative regulation of toll-like receptor activity in fibrosis: potential targets for therapeutic intervention","volume":"5","author":"Bale","year":"2021","journal-title":"AIMS Allergy Immunol"},{"issue":"2","key":"10.1016\/j.jmccpl.2026.100860_bb0270","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s00109-017-1608-3","article-title":"A20 prevents obesity-induced development of cardiac dysfunction","volume":"96","author":"Xu","year":"2018","journal-title":"J Mol Med"},{"issue":"4","key":"10.1016\/j.jmccpl.2026.100860_bb0275","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1161\/HYPERTENSIONAHA.115.06004","article-title":"Tenascin-C may accelerate cardiac fibrosis by activating macrophages via the integrin \u03b1V\u03b23\/nuclear factor-\u03baB\/interleukin-6 axis","volume":"66","author":"Shimojo","year":"2015","journal-title":"Hypertension"},{"issue":"5","key":"10.1016\/j.jmccpl.2026.100860_bb0280","doi-asserted-by":"crossref","first-page":"C781","DOI":"10.1152\/ajpcell.00353.2020","article-title":"Tenascin-C in cardiac disease: a sophisticated controller of inflammation, repair, and fibrosis","volume":"319","author":"Imanaka-Yoshida","year":"2020","journal-title":"Am J Physiol Cell Physiol"},{"issue":"3","key":"10.1016\/j.jmccpl.2026.100860_bb0285","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1074\/jbc.M109.051961","article-title":"Incorporation of tenascin-C into the extracellular matrix by periostin underlies an extracellular meshwork architecture *","volume":"285","author":"Kii","year":"2010","journal-title":"J Biol Chem"},{"issue":"2","key":"10.1016\/j.jmccpl.2026.100860_bb0290","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2025.111756","article-title":"Negative regulation of lymphangiogenesis by tenascin-C delays the resolution of inflammation","volume":"28","author":"Katoh","year":"2025","journal-title":"iScience"},{"key":"10.1016\/j.jmccpl.2026.100860_bb0295","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/613249","article-title":"Carbon monoxide inhibits tenascin-C mediated inflammation via IL-10 expression in a septic mouse model","volume":"2015","author":"Uddin","year":"2015","journal-title":"Mediators Inflamm"},{"key":"10.1016\/j.jmccpl.2026.100860_bb0300","doi-asserted-by":"crossref","DOI":"10.3389\/fncel.2019.00363","article-title":"Brain-derived neurotrophic factor: a key molecule for memory in the healthy and the pathological brain","volume":"13","author":"Miranda","year":"2019","journal-title":"Front Cell Neurosci"},{"key":"10.1016\/j.jmccpl.2026.100860_bb0305","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.yjmcc.2017.07.007","article-title":"BDNF \u2013 a key player in cardiovascular system","volume":"110","author":"Pius-Sadowska","year":"2017","journal-title":"J Mol Cell Cardiol"},{"issue":"1","key":"10.1016\/j.jmccpl.2026.100860_bb0310","doi-asserted-by":"crossref","first-page":"17331","DOI":"10.1038\/s41598-017-17594-6","article-title":"Circulating CCL20 as a new biomarker of abdominal aortic aneurysm","volume":"7","author":"Soto","year":"2017","journal-title":"Sci Rep"},{"issue":"6","key":"10.1016\/j.jmccpl.2026.100860_bb0315","first-page":"2283","article-title":"Endoglin (CD105): a review of its role in angiogenesis and tumor diagnosis, progression and therapy","volume":"31","author":"Nassiri","year":"2011","journal-title":"Anticancer Res"},{"issue":"2","key":"10.1016\/j.jmccpl.2026.100860_bb0320","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1161\/CIRCRESAHA.119.315974","article-title":"Loss of endothelial endoglin promotes high-output heart failure through peripheral arteriovenous shunting driven by VEGF signaling","volume":"126","author":"Tual-Chalot","year":"2020","journal-title":"Circ Res"},{"issue":"9","key":"10.1016\/j.jmccpl.2026.100860_bb0325","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/S1043-2760(01)00441-6","article-title":"Apoptosis induced by FasL and TRAIL\/Apo2L in the pathogenesis of thyroid diseases","volume":"12","author":"Mitsiades","year":"2001","journal-title":"Trends Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.jmccpl.2026.100860_bb0330","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1172\/JCI13779","article-title":"Fas receptor signaling inhibits glycogen synthase kinase 3 beta and induces cardiac hypertrophy following pressure overload","volume":"109","author":"Badorff","year":"2002","journal-title":"J Clin Invest"},{"issue":"7","key":"10.1016\/j.jmccpl.2026.100860_bb0335","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24076501","article-title":"Galectin-1: a traditionally immunosuppressive protein displays context-dependent capacities","volume":"24","author":"Yu","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"11","key":"10.1016\/j.jmccpl.2026.100860_bb0340","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1016\/j.ajpath.2018.07.016","article-title":"Heparin-binding epidermal growth factor-like growth factor as a critical mediator of tissue repair and regeneration","volume":"188","author":"Dao","year":"2018","journal-title":"Am J Pathol"},{"issue":"7","key":"10.1016\/j.jmccpl.2026.100860_bb0345","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1038\/labinvest.3700282","article-title":"Local overexpression of HB-EGF exacerbates remodeling following myocardial infarction by activating noncardiomyocytes","volume":"85","author":"Ushikoshi","year":"2005","journal-title":"Lab Invest"},{"issue":"5","key":"10.1016\/j.jmccpl.2026.100860_bb0350","doi-asserted-by":"crossref","first-page":"H587","DOI":"10.1152\/ajpheart.00298.2012","article-title":"Interferon-\u03b3 ablation exacerbates myocardial hypertrophy in diastolic heart failure","volume":"303","author":"Garcia","year":"2012","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"6","key":"10.1016\/j.jmccpl.2026.100860_bb0355","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.117.008145","article-title":"Protective roles of interferon-\u03b3 in cardiac hypertrophy induced by sustained pressure overload","volume":"7","author":"Kimura","year":"2018","journal-title":"J Am Heart Assoc"},{"issue":"12","key":"10.1016\/j.jmccpl.2026.100860_bb0360","first-page":"1691","article-title":"Targeting P-selectin adhesion molecule in molecular imaging: P-selectin expression as a valuable imaging biomarker of inflammation in cardiovascular disease","volume":"60","author":"Perkins","year":"2019","journal-title":"J Nucl Med Off Publ Soc Nucl Med"},{"issue":"24","key":"10.1016\/j.jmccpl.2026.100860_bb0365","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1016\/j.ehj.2003.08.021","article-title":"The adhesion molecule P-selectin and cardiovascular disease","volume":"24","author":"Blann","year":"2003","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jmccpl.2026.100860_bb0370","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.724107","article-title":"A transcriptional signature of PDGF-DD activated natural killer cells predicts more favorable prognosis in low-grade glioma","volume":"12","author":"Sun","year":"2021","journal-title":"Front Immunol"},{"issue":"12","key":"10.1016\/j.jmccpl.2026.100860_bb0375","doi-asserted-by":"crossref","first-page":"H1719","DOI":"10.1152\/ajpheart.00130.2013","article-title":"Platelet-derived growth factor-D promotes fibrogenesis of cardiac fibroblasts","volume":"304","author":"Zhao","year":"2013","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"6","key":"10.1016\/j.jmccpl.2026.100860_bb0380","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1111\/joim.12675","article-title":"Plasma stem cell factor levels are associated with risk of cardiovascular disease and death","volume":"282","author":"Bj\u00f6rkbacka","year":"2017","journal-title":"J Intern Med"},{"key":"10.1016\/j.jmccpl.2026.100860_bb0385","doi-asserted-by":"crossref","first-page":"3808","DOI":"10.12659\/MSM.906038","article-title":"Platelet derived growth factor alpha (PDGFR\u03b1) induces the activation of cardiac fibroblasts by activating c-kit","volume":"23","author":"Wang","year":"2017","journal-title":"Med Sci Monit"},{"issue":"5","key":"10.1016\/j.jmccpl.2026.100860_bb0390","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1016\/j.athoracsur.2011.06.057","article-title":"Transforming growth factor-\u03b1 enhances stem cell-mediated postischemic myocardial protection","volume":"92","author":"Herrmann","year":"2011","journal-title":"Ann Thorac Surg"},{"issue":"4","key":"10.1016\/j.jmccpl.2026.100860_bb0395","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s10456-006-9055-8","article-title":"Vascular endothelial growth factor receptor-1 (VEGFR-1\/Flt-1): a dual regulator for angiogenesis","volume":"9","author":"Shibuya","year":"2006","journal-title":"Angiogenesis"},{"issue":"15","key":"10.1016\/j.jmccpl.2026.100860_bb0400","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21155294","article-title":"VEGF-A in cardiomyocytes and heart diseases","volume":"21","author":"Braile","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"8","key":"10.1016\/j.jmccpl.2026.100860_bb0405","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1093\/cvr\/cvaa291","article-title":"The physiological and pathological functions of VEGFR3 in cardiac and lymphatic development and related diseases","volume":"117","author":"Monaghan","year":"2021","journal-title":"Cardiovasc Res"},{"issue":"4","key":"10.1016\/j.jmccpl.2026.100860_bb0410","first-page":"697","article-title":"VEGF-C\/VEGFR-3 pathway promotes myocyte hypertrophy and survival in the infarcted myocardium","volume":"7","author":"Zhao","year":"2015","journal-title":"Am J Transl Res"}],"container-title":["Journal of Molecular and Cellular Cardiology Plus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772976126000279?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772976126000279?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T06:44:04Z","timestamp":1789627444000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2772976126000279"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":82,"alternative-id":["S2772976126000279"],"URL":"https:\/\/doi.org\/10.1016\/j.jmccpl.2026.100860","relation":{},"ISSN":["2772-9761"],"issn-type":[{"value":"2772-9761","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"SGLT2 inhibitor therapy is associated with IL-10\/TGF-\u03b1\/sVEGFR3 signalling and adipose tissue remodelling in advanced heart failure","name":"articletitle","label":"Article Title"},{"value":"Journal of Molecular and Cellular Cardiology Plus","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jmccpl.2026.100860","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100860"}}